Table 1.
Baseline characteristics of study participants
| Variable | Moxifloxacin | Ethambutol | All | |
|---|---|---|---|---|
| N | 74 | 72 | 146 | |
| Age (years) – mean(SD) | 32.5 (11.7) | 35.7 (12.0) | 34.1 (11.9) | |
| Sex | ||||
| Male | 41 (55%) | 50 (69%) | 91 (62%) | |
| Female | 33 (45%) | 22 (31%) | 55 (38%) | |
| Race | ||||
| Non-white | 44 (59%) | 40 (56%) | 84 (58%) | |
| White | 30 (41%) | 32 (44%) | 62 (42%) | |
| HIV Seropositive | 3 (4%) | 2 (3%) | 5 (3%) | |
| Socio-economic status | ||||
| Mean income (SD) (reais/month) |
636 (550) | 847 (724) | 738 (647) | |
| Formal employment | 35 (47%) | 41 (57%) | 76 (52%) | |
| Weight (kg) – mean(SD) | 54.3 (9.6) | 58.2 (9.9) | 56.2 (9.9) | |
|
Baseline Sputum Acid Fast Bacilli Smear |
||||
| < 1 per hpf* | 42 (57%) | 33 (46%) | 75 (51%) | |
| 1–10 per hpf | 10 (14%) | 17 (24%) | 27 (18%) | |
| >10 per hpf | 22 (30%) | 22 (31%) | 44 (30%) | |
| Baseline x-ray | ||||
| Infiltrate | 74 (100%) | 72 (100%) | 146 (100%) | |
| Bilateral disease | 34 (46%) | 31 (43%) | 65 (44.5%) | |
| Cavitation | 60 (81%) | 41 (57%) | 101 (69%) | |
| Adenopathy | 8 (11%) | 11 (15%) | 19 (13%) | |
| Pleural effusion | 4 (5%) | 7 (10%) | 11 (8%) | |
| Baseline Symptoms | ||||
| Productive Cough | 59 (80%) | 57 (79%) | 116 (79%) | |
| Hemoptysis | 25 (34%) | 20 (28%) | 45 (31%) | |
| Fever | 59 (80%) | 58 (81%) | 117 (80%) | |
| Night Sweats | 61 (82%) | 57 (79%) | 118 (81%) | |
| Weight loss | 66 (89%) | 70 (97%) | 136 (93%) | |
| Current or past smoker | 29 (39 %) | 37 (51%) | 66 (45%) | |
|
Mean days of treatment before enrollment (SD) |
6.4 (3.2) | 5.6 (2.5) | 6.0 (2.9) | |
|
Baseline Blood results – mean(SD) |
||||
| White Blood Cells (/ml) | 9324 (2961) | 9728 (3921) | 9523 (3462) | |
| Hematocrit (%) | 36.4 (5.7) | 36.9 (5.1) | 36.7 (5.4) | |
| Hemoglobin (g/dL) | 12.3 (1.8) | 12.3 (1.8) | 12.3 (1.8) | |
| Neutrophils (/ml) | 6784 (2530) | 7072 (3398) | 6926 (2983) | |
| Alkaline Phosphatase (U/L) |
116.4 (62.3) | 121.2 (49.2) | 118.7 (56.1) | |
| ALT (U/L) | 35.8 (22.3) | 35.6 (18.9) | 35.7 (20.6) | |
| AST (U/L) | 27.8 (16.3) | 26.8 (14.4) | 27.3 (15.4) | |
| Total Bilirubin (mg/dL) | 0.55 (0.35) | 0.49 (0.26) | 0.5 (0.3) | |
| GGT (U/L) | 72.6 (50.5) | 96.1 (89.3) | 84.2 (73.0) | |
| Creatinine (mg/dL) | 0.8 (0.2) | 0.8 (0.1) | 0.8 (0.2) | |
*
hpf = high power field